Standard Dosing for Severe Malaria
Artesunate is approved for intravenous use in severe malaria, with a loading dose of 2.4 mg/kg body weight on day 1, followed by 1.2 mg/kg at 12 and 24 hours, then 1.2 mg/kg daily until oral therapy starts.[1][2] This regimen, recommended by WHO and CDC, totals about 4.8-7.2 mg/kg in the first day for adults.
Maximum Safe Dosage in Trials and Guidelines
No universal "maximum safe dosage" exists due to artesunate's short half-life and weight-based dosing. Clinical trials tested up to 8 mg/kg initially without excess toxicity, but guidelines cap at 2.4 mg/kg loading to balance efficacy and risks like post-artesunate delayed hemolysis (PADH).[3][4] For children under 20 kg, doses are sometimes adjusted lower (e.g., 3 mg/kg loading in some protocols).
What Happens with Overdose or High Doses
Overdoses up to 4 mg/kg have caused reversible hepatotoxicity and mild cardiac effects in case reports, but no fatalities directly linked.[5] Animal studies show LD50 (lethal dose for 50%) exceeds 200 mg/kg IV in rats, far above human use.[6] Monitor for anemia, liver enzymes, and QT prolongation at higher doses.
Dosage Adjustments for Special Populations
- Children: Same mg/kg as adults; max single dose often limited to 120-150 mg.[2]
- Pregnancy: Up to 2.4 mg/kg safe in 2nd/3rd trimesters; avoid 1st trimester if possible.[1]
- Renal/Hepatic Impairment: No adjustment needed; short half-life allows clearance.[4]
- Obese Patients: Use ideal body weight to avoid overdose.[3]
Why No Higher Doses Are Routinely Used
Higher doses risk PADH (hemolysis 7-14 days post-treatment, dropping hemoglobin >10%) and rare hypersensitivity. Trials like SEAQUAMAT confirmed 2.4 mg/kg optimal for survival without added benefit from escalation.[7] Always transition to oral artemisinin combos within 24-48 hours.
[1]: WHO Guidelines for Malaria (2023)
[2]: CDC Yellow Book - Malaria
[3]: NEJM - Artesunate Trial (2005)
[4]: FDA Label - Artesunate (2020)
[5]: PubMed - Artesunate Overdose Case (2012)
[6]: EMA Assessment Report
[7]: Lancet - SEAQUAMAT (2005)